Moderna reported a profitable third quarter and raised its full-year revenue-growth outlook after stronger international COVID-19 vaccine sales. Its cash and investment balance also rose, but a large part of that increase came from financing rather than cash generated by sales.
That distinction is useful for investors assessing a biotechnology company with seasonal revenue and substantial research spending. A stronger cash balance can give a business more flexibility, but its source matters when evaluating how the company will fund operations and product development over time.
In its November 6, 2026 earnings release furnished to the SEC, Moderna reported $1.3 billion in third-quarter revenue, up 29% from a year earlier, and net income of $162 million. All figures in this article are U.S. dollars.
What changed in the quarter?
Revenue rose from about $1.0 billion in the prior-year quarter. Moderna attributed the increase primarily to higher international COVID vaccine sales, supported by deliveries under long-term government partnerships. It reported $780 million of revenue in the United States and $533 million internationally.
The company moved from a $200 million net loss in the third quarter of 2025 to $162 million in net income in the latest quarter. Diluted earnings per share were $0.38, compared with a loss of $0.51 per share a year earlier. These are reported results under generally accepted accounting principles.
The increase in revenue was not the only change. Research and development expenses fell 27% to $583 million. Moderna attributed the decline in part to the completion and wind-down of certain late-stage infectious disease studies, along with cost efficiencies.
A lower expense can improve reported profit, but an investor should also ask what activities changed and what spending may be needed for future products. Research costs do not behave like a fixed subscription that can always be reduced without affecting the business.
Why did cash and investments increase?
Moderna reported $8.0 billion in cash, cash equivalents and investments at September 30, compared with $6.9 billion at June 30. The balance increased even though the company said it used cash in operations during the quarter.
The release says the increase primarily reflected $2.6 billion in net proceeds from convertible notes and related capped call transactions. That was partly offset by a $950 million litigation settlement payment and operating cash use, including a seasonal working-capital effect.
The company also said that most proceeds from third-quarter product sales remained uncollected at the end of the quarter. Revenue and cash receipts do not always arrive at the same time. A sale recognized in the accounts can create a receivable that is collected later.
For an investor, the relevant questions are not merely whether cash increased, but how much came from financing, when receivables are collected and what future obligations accompany the financing. A larger bank balance funded by borrowing is different from a larger balance built entirely through recurring operating cash flow.
What are convertible notes?
Convertible notes are debt instruments that may be converted into shares under specified terms. Until conversion or repayment, they are obligations of the issuer. Their detailed economics depend on interest, maturity, conversion conditions and any related transactions.
A capped call is a separate transaction often used alongside convertible financing to help manage potential dilution or share-price exposure under particular conditions. Its actual effect depends on the contract terms and future share price. The company’s filings are the appropriate place to examine those details.
The financing can provide cash today while creating future costs or potential dilution. That is neither automatically good nor automatically bad. It is a capital-allocation choice that should be evaluated alongside Moderna’s development plans, cash needs and alternative funding options.
What does the new outlook say?
Moderna now expects total revenue to grow 15% to 25% in 2026, compared with its previous expectation of up to 10% growth. It expects year-end cash and investments of $8.1 billion to $8.3 billion, compared with a previous range of $4.7 billion to $5.2 billion.
The company says the higher cash outlook reflects improved operational execution and proceeds from the convertible financing. This is a forecast, not a completed year-end result. Actual revenue, spending and cash balances can differ if deliveries, collections, expenses or other assumptions change.
Moderna also lowered its expected 2026 research and development expense to approximately $2.7 billion from about $2.9 billion. A full-year forecast is useful context, but the timing of clinical programs and investments can make individual quarters uneven.
Why does seasonality matter?
Vaccines for respiratory diseases are often used around particular seasons. Product deliveries, government orders and the timing of customer payments can therefore affect quarterly comparisons. A profitable quarter during a strong sales period does not, by itself, prove that every quarter will be profitable.
Likewise, a weaker quarter does not necessarily tell the whole story about a full year. Investors can compare the same quarter across years, examine year-to-date cash flow and read the company’s discussion of delivery timing. Even year-over-year comparisons can be affected by changes in public-health recommendations and purchasing patterns.
Reuters reported that international vaccine demand and partnership payments contributed to the quarter’s result. The company’s own release attributes the revenue increase primarily to international COVID vaccine sales. Both descriptions should be read alongside the detailed financial statements rather than treated as a guarantee of future demand.
What role does the product pipeline play?
Biotechnology investors often look beyond current product sales to studies and regulatory decisions that might affect future revenue. Moderna described its influenza vaccine approvals and reported positive Phase 3 results for intismeran combined with Keytruda in a particular high-risk melanoma setting.
Clinical results need careful interpretation. The company’s release describes a comparison in a defined study population, and future submissions or commercialization remain subject to regulatory decisions. A study result in one setting does not prove effectiveness for every cancer, every patient or every treatment combination.
The pipeline also carries uncertainty. Moderna said an interim analysis of its norovirus vaccine did not meet the statistical criteria for early success and that it planned to discuss the program with health authorities. A portfolio can contain encouraging and disappointing developments at the same time.
What should investors watch next?
Follow whether receivables convert into cash as expected and how operating cash flow develops across the full seasonal cycle. Review the terms and potential dilution associated with convertible financing, and compare actual spending with the company’s forecast.
For the pipeline, distinguish announced study findings from approvals, launches and eventual commercial sales. Each is a separate milestone. Revenue growth, a quarterly profit and a larger cash balance are meaningful, but none alone establishes the company’s long-term value or the future direction of its shares.
This article is educational and does not provide personalized investment advice.
Explore the book: How to Do Hard Things: The Discomfort Trap
Be First to Comment